

SUPPLEMENTARY MATERIAL

Role of Dolutegravir/Lamivudine in the Management of Pregnant People Living With

HIV-1: A Narrative Review

William R. Short,¹ Parul Patel,² Gustavo Verdier,³ Ana Puga,² Vani Vannappagari,² Annemiek de Ruiter,⁴ Bryn Jones⁴

¹Department of Medicine, Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Medical Arts Building, 3801 Filbert Street, Suite 103, Philadelphia, PA, USA 19104; ²ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC, USA 27701;

³ViiV Healthcare, 75 Queen Street, Suite 1400, Montréal, Québec, H3C 2N6, Canada; ⁴ViiV Healthcare, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK

Corresponding author: William R. Short, MD, MPH, FIDSA;

William.Short@pennmedicine.upenn.edu


Figure S1. Role of Dolutegravir/Lamivudine in the Management of Pregnant People Living With HIV-1

Role of Dolutegravir/Lamivudine in the Management of Pregnant People Living With HIV-1: A Narrative Review

William R. Short, Parul Patel, Gustavo Verdier, Ana Puga, Vani Vannappagari, Annemiek de Ruiter, Bryn Jones



A guiding principle during pregnancy is minimizing fetal exposure to drugs



When **choosing ART** for use in pregnancy, it is important to consider available data on

- 📍 **Efficacy** in non-pregnant and/or pregnant adults
- 📍 **PK** in pregnancy
- 📍 **Pregnancy safety and outcomes**

The **2DR DTG/3TC** has demonstrated **high efficacy** in non-pregnant individuals


Two studies evaluated **DTG/3TC** during pregnancy and reported

97% With **virologic suppression**
(30/31)

0 Vertical transmission events

Consistent with data for **DTG-based 3DRs** in pregnancy (N=554)

DTG and 3TC PK in pregnancy is **comparable** to that in **non-pregnant adults**



Therefore, **no dose adjustment is anticipated for DTG/3TC 2DR in pregnancy**

Data indicate **no increased risk of adverse birth outcomes or defects** with DTG- and 3TC-containing 3DRs

Updated data from the **Tsepamo** and **Eswatini** surveillance studies (>14,000 DTG exposures) show **no increased risk of NTDs** with DTG

DTG/3TC is anticipated to be **effective** and **well tolerated** while **reducing fetal exposure to drugs**

ART, antiretroviral therapy; 2DR, 2-drug regimen; 3DR, 3-drug regimen; DTG, dolutegravir; NTD, neural tube defect; PK, pharmacokinetics; 3TC, lamivudine.

This graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online.